Panobinostat: first global approval.

Abstract:

:Novartis has developed oral and intravenous formulations of panobinostat (Farydak(®)), a histone deacetylase (HDAC) inhibitor, for the treatment of cancer. HDACs have important roles in maintaining chromatin structure and in regulating gene expression, including that of tumour suppressor genes, and thus represent valid targets in the search for cancer therapeutics. Oral panobinostat is approved in the US, as combination therapy with bortezomib and dexamethasone in patients with recurrent multiple myeloma who have received at least two prior treatment regimens, including bortezomib and an immunomodulatory agent. Regulatory submissions have been made for the use of combination therapy with panobinostat in patients with recurrent multiple myeloma in the EU and Japan. Panobinostat is in various stages of clinical development worldwide for a range of haematological and solid tumours. This article summarizes the milestones in the development of panobinostat leading to this first approval for multiple myeloma.

journal_name

Drugs

journal_title

Drugs

authors

Garnock-Jones KP

doi

10.1007/s40265-015-0388-8

subject

Has Abstract

pub_date

2015-04-01 00:00:00

pages

695-704

issue

6

eissn

0012-6667

issn

1179-1950

journal_volume

75

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Postanaesthetic shivering: epidemiology, pathophysiology, and approaches to prevention and management.

    abstract::Along with nausea and vomiting, postanaesthetic shivering is one of the leading causes of discomfort for patients recovering from general anaesthesia. The distinguishing factor during electromyogram recordings between patients with postanaesthetic shivering and shivering in fully awake patients is the existence of clo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161150-00004

    authors: Alfonsi P

    更新日期:2001-01-01 00:00:00

  • Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.

    abstract::A once-daily preservative-free fixed combination ophthalmic solution containing tafluprost 0.0015 % and timolol 0.5 % (hereafter referred to as tafluprost/timolol) [Taptiqom(®)] has been developed to lower intraocular pressure (IOP) whilst avoiding damage to the ocular surface associated with preservatives such as ben...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0476-9

    authors: Hoy SM

    更新日期:2015-10-01 00:00:00

  • Rilpivirine.

    abstract::Rilpivirine is an orally administered, non-nucleoside reverse transcriptase inhibitor that is a component drug in combination therapy for antiretroviral-naive patients with HIV-1 infection. The randomized, double-blind, double-dummy, multinational ECHO and THRIVE trials in antiretroviral-naive adult patients with HIV-...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208590-000000000-00000

    authors: Sanford M

    更新日期:2012-03-05 00:00:00

  • Insulin glulisine: a review of its use in the management of diabetes mellitus.

    abstract::Insulin glulisine (Apidra) is a human insulin analogue approved for the improvement of glycaemic control in adults, adolescents and children with diabetes mellitus. It has similar binding properties, and is associated with a faster onset but similar level of glucose disposal, to regular human insulin (RHI). Insulin gl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969080-00006

    authors: Garnock-Jones KP,Plosker GL

    更新日期:2009-05-29 00:00:00

  • Sirolimus use in recipients of expanded criteria donor kidneys.

    abstract::With changing donor characteristics and the growing shortage in organ supply, renal transplant practitioners have sought to optimize the use of expanded criteria donor (ECD) kidneys, which have poorer outcomes than standard criteria donor (SCD) kidneys. The outcomes may represent an acceptable trade-off if ECD transpl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868001-00006

    authors: House AA,Nguan CY,Luke PP

    更新日期:2008-01-01 00:00:00

  • Activity of cefotaxime and amikacin against 14,272 gram-negative bacteria from clinical samples in the period 1980 to 1985.

    abstract::The sensitivity to cefotaxime and amikacin of 14,272 Gram-negative bacilli (Enterobacteriaceae and non-fermenting Gram-negative bacilli) isolated from clinical samples was studied during the period 1980 to 1985. The minimum inhibitory concentration (MIC) was determined by means of diffusion in agar. Strains were consi...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198800352-00003

    authors: Dámaso D,Sánchez-Moreno MP,Martínez-Martínez L,Mesa E,Portero F,Mendaza P,Daza RM

    更新日期:1988-01-01 00:00:00

  • Fetal pharmacotherapy.

    abstract::Rapid progress has recently been encountered in pharmacologically treating the unborn baby. This unique area of drug therapy raises new methodological and ethical questions. This article is a systematic review of known modalities of fetal pharmacotherapy, and aims to highlight essential principles, difficulties and co...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262050-00004

    authors: Koren G,Klinger G,Ohlsson A

    更新日期:2002-01-01 00:00:00

  • A new strategy for the treatment of inflammatory pain. Prevention or elimination of central sensitization.

    abstract::The optimal treatment of pain requires an understanding of the mechanisms involved. Pain is a sensory end-point that can be generated by a number of dissimilar processes. Consequently, the concept of treating pain as a unitary symptom is obsolete. The mechanisms responsible for specific types of pain need to be unders...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199400475-00003

    authors: Woolf CJ

    更新日期:1994-01-01 00:00:00

  • The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.

    abstract::The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological impact of this pathway has led to the development of specific inhibitors to this pathway. Preclinical data in cell lines, patient samples and disease models have bro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0565-4

    authors: Seiler T,Hutter G,Dreyling M

    更新日期:2016-04-01 00:00:00

  • Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.

    abstract::Gefitinib (Iressa) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that offers treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), in particular in those who are harbouring EGFR mutations. In a large phase III trial (IPASS) in chemotherapy-naive Asian ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/10489100-000000000-00000

    authors: Sanford M,Scott LJ

    更新日期:2009-11-12 00:00:00

  • Clopidogrel.

    abstract::Clopidogrel is a thienopyridine that irreversibly inhibits platelet aggregation by selectively binding to adenylate cyclase-coupled ADP receptors on the platelet surface. In animal models, clopidogrel reduced the formation of both arterial and venous thrombi. After oral administration, clopidogrel is rapidly absorbed ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754050-00006

    authors: Coukell AJ,Markham A

    更新日期:1997-11-01 00:00:00

  • Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments.

    abstract::Non-insulin-dependent diabetes mellitus (NIDDM, type 2 diabetes) is a heterogeneous disease resulting from a dynamic interaction between defects in insulin secretion and insulin action. There are various pharmacological approaches to improving glucose homeostasis, but those currently used in clinical practice either d...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754030-00001

    authors: Scheen AJ

    更新日期:1997-09-01 00:00:00

  • Pharmacology and therapeutic use of calcitonin.

    abstract::Calcitonin is a peptide hormone secreted by the C-cells of the thyroid gland. A major physiological function of the hormone appears to be the protection of the skeleton against resorption in humans. It thus opposes the resorptive actions of parathyroid hormone and 1,25 dihydroxyvitamin D. This action is utilised pharm...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198121040-00002

    authors: Stevenson JC,Evans IM

    更新日期:1981-04-01 00:00:00

  • Insulin glargine: an updated review of its use in the management of diabetes mellitus.

    abstract::Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the formation of a stable compound that is soluble at pH 4.0, but forms amorphous microprecipitates in subcutaneous tissue from...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验,评审

    doi:10.2165/00003495-200363160-00007

    authors: Dunn CJ,Plosker GL,Keating GM,McKeage K,Scott LJ

    更新日期:2003-01-01 00:00:00

  • The challenge of changing healthcare systems.

    abstract::Healthcare systems are in flux throughout the world. Traditional structures and attitudes are changing. The balance of power between political bodies, payers, providers and patients is being destabilised. New approaches by governments and forward integration by drug companies and payers into care management are all ma...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-199600522-00014

    authors: Weber F

    更新日期:1996-01-01 00:00:00

  • Quinidine and digoxin. An important interaction.

    abstract::An increase in serum digoxin concentration occurs in 90% of patients given quinidine. On average, the serum digoxin doubles during treatment with therapeutic doses of quinidine. Almost every patient treated with quinidine will have a decrease in the renal clearance of digoxin and many will have a decrease in the volum...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198224030-00003

    authors: Bigger JT Jr,Leahey EB Jr

    更新日期:1982-09-01 00:00:00

  • [Pain management: health economics and quality of life considerations].

    abstract::Pain represents a major clinical, social and economic problem, with estimates of its prevalence ranging from 8% to more than 60%, depending on the population. The impact of pain on economies is enormous, with the cost of back pain alone equivalent to more than one-fifth of one country's total health expenditure and 1....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Phillips CJ

    更新日期:2003-01-01 00:00:00

  • Pharmacological and biochemical actions of sulphasalazine.

    abstract::This review considers recent pharmacological and biochemical studies of sulphasalazine and its colonic metabolites, 5-aminosalicylic acid and sulphapyridine, in relation to the use of the parent drug for the treatment of ulcerative colitis and, more recently, rheumatoid arthritis. Several factors make it difficult to ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198600321-00005

    authors: Hoult JR

    更新日期:1986-01-01 00:00:00

  • Zonisamide: a review of its use in the management of adults with partial seizures.

    abstract::Oral zonisamide (Zonegran(®)) is a benzisoxazole derivative chemically unrelated to other antiepileptic agents. It is indicated in the EU as monotherapy in the treatment of partial seizures, with or without secondary generalization, in adults with newly diagnosed epilepsy and as adjunctive therapy to other antiepilept...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0093-4

    authors: Hoy SM

    更新日期:2013-08-01 00:00:00

  • Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.

    abstract::Biologics and biosimilars are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases. They are highly targeted, efficacious, and represent an increasingly important part of physicians' armamentaria in the combat against th...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-018-1009-0

    authors: Chen BK,Yang YT,Bennett CL

    更新日期:2018-11-01 00:00:00

  • Treatment options for sleep apnoea.

    abstract::Sleep apnoea (SA) is a common sleep disorder affecting 4 to 25% of the adult population. The most common form, obstructive SA, is characterised by recurrent upper airway obstruction during sleep associated with sleep disruption and hypoxaemia. There is increasing evidence that SA leads to impaired vigilance, quality o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161020-00007

    authors: Grunstein RR,Hedner J,Grote L

    更新日期:2001-01-01 00:00:00

  • Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension.

    abstract::Mild to moderate hypertension still remains poorly controlled. This relates to multiple factors including low antihypertensive efficacy of single drug therapies reluctance of primary care physicians to modify/titrate initially chosen therapy to obtain target blood pressure, and poor compliance with medication. Several...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161070-00004

    authors: Ruzicka M,Leenen FH

    更新日期:2001-01-01 00:00:00

  • Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer.

    abstract::Patients with oncogene-driven lung cancer have limited therapeutic options after progressing on their targeted tyrosine kinase inhibitor (TKI) therapy. Given the growing role of immune checkpoint inhibitor (ICI) therapy in the treatment of lung cancer, oncogene-driven cancer has warranted further evaluation regarding ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01320-0

    authors: Somasundaram A,Socinski MA,Villaruz LC

    更新日期:2020-06-01 00:00:00

  • Everolimus.

    abstract::Everolimus is an immunosuppressant that blocks growth factor-mediated proliferation of haematopoietic and nonhaematopoietic cells. Oral everolimus 0.75 or 1.5mg twice daily significantly reduced the incidence of the primary composite endpoint, efficacy failure 6 months after transplantation, compared with azathioprine...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200464080-00005

    authors: Chapman TM,Perry CM

    更新日期:2004-01-01 00:00:00

  • Sotagliflozin: A Review in Type 1 Diabetes.

    abstract::Sotagliflozin (Zynquista™) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2). In the phase 3, inTANDEM 1-3 trials, adjunctive use of oral sotagliflozin (200 mg or 400 mg once daily) improved glycaemic control and reduced bodyweight and insulin requirements relative to placebo over 24 ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01230-w

    authors: Deeks ED

    更新日期:2019-12-01 00:00:00

  • Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

    abstract::Remifentanil (Ultiva), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-metabolised, selective mu-opioid receptor agonist, with a pharmacodynamic profile typical of opioid analgesic agents. Notably, the esterase linkage in remifentanil results in a unique and favourable pharmacokinetic profile for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565130-00007

    authors: Scott LJ,Perry CM

    更新日期:2005-01-01 00:00:00

  • Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.

    abstract::Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects. In open short- and long-term studies benzbromarone reduced serum uric acid levels by one-third to one-half and maintained its effectiveness for periods of up to 8 years...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197714050-00002

    authors: Heel RC,Brogden RN,Speight TM,Avery GS

    更新日期:1977-11-01 00:00:00

  • Drug-induced hypertension: pathogenesis and management.

    abstract::Estrogenic compounds are the most important group of drugs that can induce hypertension. Studies have shown an incidence of significant hypertension amounting to less than 1% after 1 year of taking oral contraceptives and about 2% after 5 years. The ratio of the incidence of hypertension among ''takers'' to that of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197612030-00005

    authors: Stokes GS

    更新日期:1976-01-01 00:00:00

  • Oral vs inhaled asthma therapy. Pros, cons and combinations.

    abstract::A number of oral and inhaled drugs are available for the long term management of patients with persistent asthma, yet the disease continues to be associated with significant morbidity and mortality. Over the past years, inhaled glucocorticoids have become established as a cornerstone of maintenance therapy because of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199600526-00005

    authors: Fabbri LM,Piattella M,Caramori G,Ciaccia A

    更新日期:1996-01-01 00:00:00

  • Alirocumab: First Global Approval.

    abstract::Alirocumab (Praluent®) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi that has been approved in the US as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic car...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0469-8

    authors: Markham A

    更新日期:2015-09-01 00:00:00